Teva Pharmaceutical Industries Limited filings document material events, operating and financial results, capital-structure matters, governance, and shareholder voting for the Israel-based pharmaceutical issuer. Its 8-K reports include results announcements, conference-related outlook disclosures, and material definitive agreements, including amendments to a senior unsecured sustainability-linked revolving credit facility.
Teva's proxy materials cover annual meeting procedures, shareholder proposals, governance matters, and annual consolidated financial statements. The filing record also identifies the company's American Depositary Shares, each representing one ordinary share, as securities registered for trading under TEVA on the New York Stock Exchange.
Teva Pharmaceutical Industries Ltd. executive vice president and chief financial officer Eliyahu Sharon Kalif exercised restricted share units into ordinary shares on March 3, 2026.
He converted 49,800 and 141,478 restricted share units, resulting in 248,756 ordinary shares held directly as of that date.
TEVA PHARMACEUTICAL INDUSTRIES LTD executive Eric A. Hughes reported multiple equity transactions on March 3, 2026. He exercised restricted share units, converting 24,900 and 141,478 units into ordinary shares at a stated price of $0.0000 per share, reflecting vesting and performance-based awards.
Following these conversions, Hughes conducted open-market sales of ordinary shares, totaling 80,762 shares at a weighted average price of $32.3599 per share, with individual sale prices ranging from $31.72 to $32.865. According to the disclosure, part of the sale represented shares required to be sold to cover tax withholding obligations, and the overall transactions were executed under a Rule 10b5-1 trading plan adopted on November 10, 2025.
Teva Pharmaceutical Industries Limited reports a Form 144 notice for proposed sale of 20,461 ordinary shares tied to a restricted share unit award vesting on 03/04/2026. The filing lists Citigroup Global Markets Inc. as the broker and classifies the disposition as compensation-related.
Teva Pharmaceutical Industries reported insider sales by Richard Francis. The filing shows sales of 447,678 ordinary shares on 02/17/2026 for $15,324,799.05 and 442,935 ordinary shares on 03/03/2026 for $14,333,332.31. The notice also lists a Restricted Share Unit award vesting of 50,223 ordinary shares with a date labeled 03/04/2024 and an entry dated 03/04/2026 under compensation.
Teva Pharmaceutical Industries Limited Form 144 lists a proposed sale of ordinary shares to be handled through Citigroup Global Markets. The filing also records a prior sale by Eric Hughes of 80,762 shares on 03/03/2026 for $2,613,450.24 and a restricted share unit award of 23,251 scheduled with a 03/04/2026 vesting/compensation reference.
Teva Pharmaceutical Industries Limited reported a proposed sale of 91,345 ordinary shares through Citigroup Global Markets Inc. with an apparent aggregate value of $2,983,515.95, dated 03/04/2026. The filing lists recent dispositions by Daniell Richard of 115,468 shares on 12/09/2025 for $3,311,131.04 and 128,985 shares on 03/03/2026 for $4,173,941.70.
Teva Pharmaceutical Industries reported a Form 144 notice relating to proposed sales of its ordinary shares. The filing lists a restricted share unit award of 3,461 shares vesting on 03/03/2026. The filing also discloses insider sales by Brian Savage: 450 shares sold on 01/30/2026 and 1,000 shares sold on 12/12/2025.
Teva Pharmaceutical Industries Limited submitted a Form 144 reporting proposed sales of ordinary shares through Citigroup Global Markets Inc., with transactions and vested compensation-related shares listed and one recent sale reported. The filing lists vested awards scheduled 03/03/2026 and a sale by Richard Francis on 02/17/2026 for 447,678 shares with amount 15324799.05.
Teva Pharmaceutical Industries disclosed a Form 144 notice reporting intended sales of ordinary shares. The filing lists restricted and performance share unit awards vesting on 03/03/2026 with quantities of 24,900, 110,668, and 30,810 shares tied to compensation awards. The broker listed is Citigroup Global Markets.
Teva Pharmaceutical Industries reports an insider Form 144 disclosing a sale of ordinary shares and upcoming compensation vesting. The filing shows 115,468 ordinary shares sold by Daniell Richard on 12/09/2025 for $3,311,131.04. The filing also lists compensation awards scheduled to vest on 03/03/2026: a Performance Share Unit award of 141,478 shares, Restricted Share Units of 24,900 shares, and Restricted Share Units (retention) of 37,350 shares.